Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel
NASDAQ:INCR

InterCure Q2 2025 Earnings Report

InterCure logo
$0.85 -0.10 (-10.38%)
Closing price 03:59 PM Eastern
Extended Trading
$0.86 +0.01 (+1.40%)
As of 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

InterCure EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InterCure Revenue Results

Actual Revenue
$19.25 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InterCure Announcement Details

Quarter
Q2 2025
Date
10/8/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

InterCure Earnings Headlines

InterCure Ltd. Reports NIS 270 Million Revenue and Positive Cash Flow for 2025 Amid Recovery Efforts
April 30, 2026  |  quiverquant.comQ
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285596/0/en/intercure-announces-2025-results-with-nis-270-million-in-revenue-and-positive-operating-cash-flow.html
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
June 10 at 1:00 AM  |  Brownstone Research (Ad)
InterCure Ltd: InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
March 4, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67850314-intercure-ltd-intercure-receives-nasdaq-notification-regarding-minimum-bid-requirement-399.htm
InterCure Ltd. Receives Nasdaq Compliance Notice Due to Bid Price Deficiency, Plans to Regain Compliance
March 3, 2026  |  quiverquant.comQ
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
March 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/03/3248978/0/en/intercure-receives-nasdaq-notification-regarding-minimum-bid-requirement.html
See More InterCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InterCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InterCure and other key companies, straight to your email.

About InterCure

InterCure (NASDAQ:INCR) Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives. The company’s in-house R&D team works in collaboration with academic and medical institutions to explore novel therapeutic applications of cannabinoids. InterCure’s product portfolio includes standardized oils, capsules and topical formulations designed to address specific clinical indications and patient preferences.

Beyond its domestic footprint, InterCure has entered strategic partnerships aimed at exporting medical cannabis products to select European and Latin American markets. These collaborations are structured to meet local regulatory requirements and quality standards, offering a pathway for InterCure’s intellectual property and high-potency strains to reach new patient populations.

Looking forward, InterCure is focused on scaling its production capacity, enhancing process efficiencies and expanding its international presence through licensing agreements and joint ventures. The company continues to invest in clinical research, advanced processing technologies and new product development as it seeks to establish a broader footprint in the evolving global medical cannabis industry.

View InterCure Profile
Earnings Tools